BioFi
BioFi AG is a Basel-based biotech software company building the EndoGenics™ simulation platform, using causal, omics-constrained disease modeling to help pharmaceutical and biotechnology companies validate targets, characterize mechanisms of action, and stratify patients for clinical trials.
- Company typePrivate
- Founded-
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What BioFi does
BioFi AG is a Basel, Switzerland-based private biotech software company that operates from the Novartis Campus with an eight-person team. It targets pharmaceutical and biotechnology companies and builds computational tools aimed at reducing translational risk in drug discovery. The company's core offering is EndoGenics™, a mechanism-based modeling and simulation platform developed from first principles; its computational core, the Endogenics Simulation Engine (ESE), was launched in July 2025. The platform integrates multi-omics inputs—including targeted plasma proteomics, bulk RNA-seq, longitudinal biomarker trajectories, and multi-cohort validation datasets—to build directed mechanistic networks and simulate relative system behavior under different target perturbations, enabling target validation, mechanism-of-action characterization, and patient stratification.
BioFi's product strategy is anchored on addressing the industry-wide 8.4% clinical trial success rate by moving from static, pattern-based prediction to dynamic causal simulation. A second product, EndoClinics™, is in development as a clinical-outcome UI initially focused on post-acute COVID-19 complications under the Horizon Europe–funded POINT project. The company's moat rests on its proprietary simulation architecture, multi-omics data integration, and a specialized team spanning computational science, bioinformatics, and software engineering.
BioFi monetizes through fee-based software services and non-exclusive commercial model licenses, with contracts priced in Swiss Francs under multi-year terms as referenced in its Terms of Service. Go-to-market is direct enterprise engagement via contact forms, email ([email protected]), and "Partner with Us" calls to action, supplemented by content marketing (blog, newsletter via MailerLite) and event participation through collaborator networks. No customer logos, pricing tiers, or revenue figures are disclosed, and the EndoGenics platform is still labeled Beta, indicating a pre-commercial or early-pilot commercial stage.
BioFi firmographics
Firmographics- Name
- BioFi
- Legal name
- BioFi AG
- Website
- https://biofi.ch
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioFi AG is a Basel-based biotech software company building the EndoGenics™ simulation platform, using causal, omics-constrained disease modeling to help pharmaceutical and biotechnology companies validate targets, characterize mechanisms of action, and stratify patients for clinical trials.
- Ownership category
- akta.pro rank
BioFi industry classification
Industry- Product category
- Drug Discovery & Computational Biology Software
- NAICS
- Software Publishers (51321), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where BioFi is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
BioFi business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Fee-Based Software Services: Some services or models may require payment, as described in specific conditions. Terms of Service Section 6.2 indicates fee-based services exist. Non-exclusive commercial licenses are granted for fee-based models. Payment terms are in Swiss Francs (CHF).
- Fee-Based Models License: Non-exclusive, commercial license granted for fee-based models under Section 2.2 of Terms of Service.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Fee-based services available with specific conditions |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
BioFi product offering
Product offeringCore offering
BioFi develops and licenses the EndoGenics platform, a mechanism-based modeling and simulation software that ingests multi-omics data (proteomics, RNA-seq, biomarker trajectories) to build causal disease network models, simulate target perturbations, and predict downstream molecular evolution. The platform is aimed at pharmaceutical and biotechnology R&D teams for target identification, Mechanism of Action characterization, and patient stratification. Access is delivered as enterprise software under multi-year fee-based license and subscription agreements denominated in Swiss Francs.
Product overview
BioFi offers a platform-based approach centered on EndoGenics™, a mechanism-based modeling and simulation platform currently in Beta. EndoGenics™ is powered by the Endogenics Simulation Engine (ESE), which handles the computational simulation of disease network dynamics. A forthcoming module called EndoClinics™ is designed to provide a customized interface for clinical outcome insights. Together, these products enable cross-functional teams to generate, simulate, and analyze causal disease models from omics data within days.
Differentiator
Problem solved
Functional benefit
Brands
- EndoGenics™: A mechanism-based modeling and simulation platform developed from first principles. Includes the Endogenics Simulation Engine (ESE) for modeling and simulating complex biological processes.
- EndoClinics™
Products and services
- EndoGenics Mechanism-based modeling and simulation platform that lets pharmaceutical and biotech R&D teams generate disease models from multi-omics data, simulate signal propagation over time, test mechanistic hypotheses, and predict downstream molecular evolution. Currently in Beta, delivered as enterprise software with account creation.
Quantifiable outcome
- Overall drug clinical trial success rate is 8.4% - target validation without clinical context and insufficient mechanistic understanding are identified as major reasons for high clinical attrition
- +1 more outcomes
Companies that use BioFi
Customer profileSegments2 records
Ideal customer profiles1 record
BioFi technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
BioFi partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- European Commission (POINT Project)coreThe POINT (Post-acute fOllow-up of non-communicable disease InTerventions) project is a Horizon Europe funded initiative. BioFi participates in developing innovative strategies for prevention and management of non-communicable diseases arising as complications during the post-acute phase of COVID-19. This represents a significant research collaboration with EU funding and co-development of disease management strategies.
- Swiss Economic Institute (SERI)minorListed as a collaborator and supporter on BioFi's website. SERI is Switzerland's federal institute supporting innovation and technology transfer.
- Region of DenmarkminorListed as a collaborator and supporter. Regional government body that may provide regional support and innovation funding.
- Basel AreaminorListed as a collaborator and supporter. Innovation hub and economic development agency for the Basel region supporting life sciences companies.
- University of Copenhagen (UCPH)coreListed as a collaborator. University partnership providing academic research collaboration and access to bioinformatics expertise and omics data resources.
- University of TartucoreListed as a collaborator. University partnership for research collaboration in bioinformatics and life sciences.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
BioFi competitors and assessment
Company assessmentDirect peers
- Insitro: Insitro combines ML with high-throughput biology and multi-omic data to model disease biology for pharma partners — closely comparable to BioFi in target identification, mechanistic modeling, and patient stratification use cases.
- Schrödinger: Schrödinger provides physics-based computational software (including AI-augmented workflows) for molecular simulation and drug discovery — directly comparable to BioFi's EndoGenics Simulation Engine approach as scientific modeling software for pharma.
- Owkin: Owkin uses AI and multi-omics patient data to inform drug development and clinical trial design — comparable to BioFi in causal disease modeling, patient stratification, and multi-omic biomarker integration.
- Recursion Pharmaceuticals: Recursion operates an AI/ML-driven drug discovery platform combining high-throughput biology with computational modeling. Although broader in scope, both companies share the AI-enabled biology platform business model targeting pharma R&D.
- Aitia: Aitia (formerly GNS Healthcare) builds causal AI and 'Digital Twins' for drug discovery using multi-omics data — directly comparable to BioFi's mechanism-based causal simulation approach for target identification and MoA characterization.
- Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company using generative and predictive ML for target identification and chemistry — comparable to BioFi as a competing AI platform positioned to reduce clinical trial attrition.
Emerging players
- Turbine AI: Turbine builds a simulation platform that models cancer biology to identify targets and combination therapies — overlaps with BioFi's simulation-driven mechanistic approach for pharma R&D.
- CytoReason: CytoReason builds AI-driven computational disease models integrating multi-omics and clinical data for pharma R&D — directly comparable to BioFi in using multi-omics data to model disease biology and guide drug discovery.
Broad incumbents
- Certara: Certara is a leading provider of biosimulation and modeling software for drug development — comparable as a broader incumbent offering mechanism-aware modeling and simulation tools to pharma R&D teams.
- BenevolentAI: BenevolentAI operates an AI discovery platform combining knowledge graphs and ML for target identification — overlaps BioFi's target ID & validation positioning with a broader, more established (and Europe-based) commercial footprint.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
BioFi social profiles
Digital presenceBioFi financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioFi leadership team
Management profileNumber of profiles
Profiles8 records
BioFi funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioFi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioFi
What does BioFi do?
BioFi develops and licenses the EndoGenics platform, a mechanism-based modeling and simulation software that ingests multi-omics data (proteomics, RNA-seq, biomarker trajectories) to build causal disease network models, simulate target perturbations, and predict downstream molecular evolution. The platform is aimed at pharmaceutical and biotechnology R&D teams for target identification, Mechanism of Action characterization, and patient stratification. Access is delivered as enterprise software under multi-year fee-based license and subscription agreements denominated in Swiss Francs.
Is BioFi a public or private company?
BioFi is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioFi founded?
BioFi was founded in -1. It employs 1 to 10 people.
Where is BioFi based?
BioFi is headquartered in Basel, Switzerland, in the Europe region.
How does BioFi make money?
Two revenue lines are on record. Fee-Based Software Services are the primary driver. The others are fee-Based Models License.
Who are BioFi's main competitors?
Direct peers on record are Insitro, Schrödinger, Owkin, Recursion Pharmaceuticals, Aitia and Insilico Medicine. Emerging players are Turbine AI and CytoReason. Broad incumbents are Certara and BenevolentAI.
Does BioFi have an API?
No public API is recorded for BioFi.
What industry is BioFi in?
BioFi's product category is Drug Discovery & Computational Biology Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 51321 and its SIC code is 7372.